187 related articles for article (PubMed ID: 31776570)
21. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
22. Case Report: Unusual Presentation of Pharyngeal Mucosal Leishmaniasis due to
Figueiredo LP; Almeida LDC; Magalhães A; Arruda S; Lessa MM; Carvalho EM
Am J Trop Med Hyg; 2020 Oct; 103(4):1493-1495. PubMed ID: 32748768
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
24. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Machado PR; Ampuero J; Guimarães LH; Villasboas L; Rocha AT; Schriefer A; Sousa RS; Talhari A; Penna G; Carvalho EM
PLoS Negl Trop Dis; 2010 Dec; 4(12):e912. PubMed ID: 21200420
[TBL] [Abstract][Full Text] [Related]
25. [Aminosidine in the treatment of mucocutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis].
Romero GA; Lessa HA; Macêdo V; de Carvalho EM; de Magalhães AV; Orge M de la G; de Abreu MV; Marsden PD
Rev Soc Bras Med Trop; 1996; 29(2):215-6. PubMed ID: 8713613
[No Abstract] [Full Text] [Related]
26. Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis.
Kosaka A; Sakamoto N; Hikone M; Imai K; Ota M; Washino T; Maeda T; Iwabuchi S
Intern Med; 2020; 59(9):1227-1230. PubMed ID: 32378656
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
28. Mucocutaneous leishmaniasis treated with liposomal amphotericin B.
Lambertucci JR; Silva LC
Rev Soc Bras Med Trop; 2008; 41(1):87-8. PubMed ID: 18368279
[No Abstract] [Full Text] [Related]
29. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid.
Motta AC; Arruda D; Souza CS; Foss NT
Int J Dermatol; 2003 Sep; 42(9):703-6. PubMed ID: 12956682
[TBL] [Abstract][Full Text] [Related]
30. Mucocutaneous leishmaniasis: case report and literature review of a rare endonasal infection.
Suqati AA; Pudszuhn A; Hofmann VM
Pan Afr Med J; 2020; 36():292. PubMed ID: 33117486
[TBL] [Abstract][Full Text] [Related]
31. Mucosal leishmaniasis presenting as sinusitis and optic neuropathy.
Huna-Baron R; Warren FA; Miller W; Jacobs J; Green J; Kupersmith MJ
Arch Ophthalmol; 2000 Jun; 118(6):852-4. PubMed ID: 10865330
[No Abstract] [Full Text] [Related]
32. Oral miltefosine to treat new world cutaneous leishmaniasis.
Soto J; Toledo JT
Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
[No Abstract] [Full Text] [Related]
33. Imported mucocutaneous leishmaniasis.
Rosbotham JL; Corbett EL; Grant HR; Hay RJ; Bryceson AD
Clin Exp Dermatol; 1996 Jul; 21(4):288-90. PubMed ID: 8974832
[TBL] [Abstract][Full Text] [Related]
34. [An evolutionary study of mucosal leishmaniasis (a 7- to 17-year follow-up) due to Leishmania (Viannia) braziliensis in Tres Braços, Bahia].
de Oliveira MR; Macêdo Vde O; de Carvalho EM; Barral A; Marotti JG; Bittencourt A; de Abreu MV; Orge M de La G; Lessa Hde A; Marsden PD
Rev Soc Bras Med Trop; 1995; 28(4):325-32. PubMed ID: 8668831
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility to Miltefosine in Brazilian Clinical Isolates of
Espada CR; Ribeiro-Dias F; Dorta ML; Pereira LIA; Carvalho EM; Machado PR; Schriefer A; Yokoyama-Yasunaka JKU; Coelho AC; Uliana SRB
Am J Trop Med Hyg; 2017 Mar; 96(3):656-659. PubMed ID: 28070006
[No Abstract] [Full Text] [Related]
36. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
38. Miltefosine Combined with Intralesional Pentamidine for
Soto J; Soto P; Ajata A; Rivero D; Luque C; Tintaya C; Berman J
Am J Trop Med Hyg; 2018 Nov; 99(5):1153-1155. PubMed ID: 30255833
[TBL] [Abstract][Full Text] [Related]
39. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis.
Solomon M; Baum S; Barzilai A; Scope A; Trau H; Schwartz E
J Am Acad Dermatol; 2007 Apr; 56(4):612-6. PubMed ID: 17276541
[TBL] [Abstract][Full Text] [Related]
40. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
